Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001683168-22-001616
Filing Date
2022-03-11
Accepted
2022-03-11 17:13:49
Documents
48
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K coeptis_i10k-123121.htm   iXBRL 10-K 778288
2 CERTIFICATION coeptis_ex3101.htm EX-31.1 8722
3 CERTIFICATION coeptis_ex3102.htm EX-31.2 8301
4 CERTIFICATIONS coeptis_ex3201.htm EX-32.1 3372
  Complete submission text file 0001683168-22-001616.txt   3358785

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE coep-20211231.xsd EX-101.SCH 25991
6 XBRL CALCULATION FILE coep-20211231_cal.xml EX-101.CAL 48066
7 XBRL DEFINITION FILE coep-20211231_def.xml EX-101.DEF 109287
8 XBRL LABEL FILE coep-20211231_lab.xml EX-101.LAB 235974
9 XBRL PRESENTATION FILE coep-20211231_pre.xml EX-101.PRE 187339
42 EXTRACTED XBRL INSTANCE DOCUMENT coeptis_i10k-123121_htm.xml XML 273103
Mailing Address 105 BRADFORD RD, SUITE 420 WEXFORD PA 15090
Business Address 105 BRADFORD RD, SUITE 420 WEXFORD PA 15090 724-934-6467
Coeptis Therapeutics Inc. (Filer) CIK: 0001819663 (see all company filings)

EIN.: 843998117 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-56194 | Film No.: 22734044
SIC: 2834 Pharmaceutical Preparations